2017.06.03 Taiwan 5 biotechs to watch special report

  • 22
  • May

2017.05.22 First Five Subjects Randomized in SyneuRx’ SND12 Phase IIb/III Study of Clozaben®, a Novel Treatment for Refractory Schizophrenia

Taipei, Taiwan, May 22, 2017 SyneuRx International (Taiwan) Corp. today announced that the first five subjects have been randomized for the company’s SND12 Phase IIb/III clinical trial. The trial will study the efficacy and safety of one of its leading investigational therapies, Clozaben®, for adult subjects with schizophrenia who are refractory to current treatments available. […]
  • 11
  • May

2017.05.11 First Three Subjects Randomized in SyneuRx’ SND13 Phase IIb/III NaBen© Schizophrenia Trial

Taipei, Taiwan, May 11, 2017 SyneuRx International (Taiwan) Corp. today announced that the first three subjects have been randomized from the 11 subjects screened into the company’s SND13 Phase IIb/III clinical trial within a short period of time.  The trial will study the efficacy and safety of its leading investigational therapy NaBen© for adult subjects […]
  • 10
  • Feb

2017.02.10 Interview: Guochuan Emil Tsai MD PhD MAS – Founder & CEO, SyneuRx, Taiwan

Pharmaboardroom.com Healthcare & Lifesciences Review Interview: Guochuan Emil Tsai MD PhD MAS – Founder & CEO, SyneuRx, Taiwan With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral sciences at the University of California, Los […]